All In Biotech

Drug Trial Radar · NCT06572228

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Actual

Start

Aug 26, 2024

Primary completion

Apr 24, 2027

Study completion Apr 24, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab

Conditions

  • Asthma

Interventions

  • dupilumabDrug

    Administered by subcutaneous (SC) injection

  • Matching PlaceboDrug

    Administered by SC injection

  • ICS/LABADrug

    Administered at a blinded dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized severe asthma exacerbation rateTime frame: Baseline through Week 52

Locations

77 sites in 6 countries. Site status is shown where the registry gives one.

  • Kern Research, Inc

    Bakersfield, California

  • Modena Allergy & Asthma, Inc.

    La Jolla, California

  • Antelope Valley Clinical Trials

    Lancaster, California

  • Ark Clinical Research, LLC

    Long Beach, California

  • Newport Native Md, Inc.

    Newport Beach, California

  • Childrens Hospital of Orange County Main Campus

    Orange, California

  • Raffi Tachdjian MD, Inc.

    Santa Monica, California

  • Bensch Clinical Research

    Stockton, California

  • Integrated Research of Inland, Inc.

    Upland, California

  • Allianz Research Institute

    Westminster, California

  • National Jewish Health

    Denver, Colorado

  • St Francis Medical Institute

    Clearwater, Florida

  • Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration

    Kissimmee, Florida

  • Clinical Site Partners, LLC DBA Flourish Research

    Winter Park, Florida

  • Treasure Valley Medical Research

    Boise, Idaho

  • Sneeze Wheeze and Itch Associates

    Normal, Illinois

  • Asthma and Allergy Center of Chicago

    River Forest, Illinois

  • Endeavor Health, Skokie Campus

    Skokie, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Bluegrass Allergy Research

    Lexington, Kentucky

  • Family Allergy and Asthma Research Institute

    Louisville, Kentucky

  • Allergy & Asthma Specialists, P.S.C.

    Owensboro, Kentucky

  • Paul A. Shapero, M.D.

    Bangor, Maine

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Michigan Medicine

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Clinical Research Institute, Inc.

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Montana Medical Research

    Missoula, Montana

  • The Asthma and Allergy Center

    Bellevue, Nebraska

  • Henderson Clinical Trials

    Henderson, Nevada

  • Certified Research Associates

    Cortland, New York

  • New York Medical College

    Hawthorne, New York

  • Northwell Health at ENT & Allergy Associates

    New York, New York

  • Rochester Regional Health - Alexander Park - Allergy, Immunology & Rheumatology

    Rochester, New York

  • Cincinnati Childrens Hospital and Medical Center

    Cincinnati, Ohio

  • Allergy Asthma and Clinical Research Center

    Oklahoma City, Oklahoma

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • University of Pittsburgh Asthma and Environmental Health Lung Institute

    Pittsburgh, Pennsylvania

  • Pulmonology Associates Inc.

    Wynnewood, Pennsylvania

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.